The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
> I assume that is a contractual amount based on the high price they paid for shares in the past.
I believe it's less to do with that and more with the provisions in Rule 9 of the Takeover Code:
https://www.thetakeoverpanel.org.uk/wp-content/uploads/2022/03/Note-to-advisers_Rule-9disclosure.0322.pdf
An offer under Rule 9 must be made in cash at the highest price paid by the person required to make the offer, or
any person acting in concert with such person, for any interest in shares of the company during the 12 months prior
to the announcement of the offer.
To date, with lack of updates, it really was all about whether you trust the (remaining) BoD or not.
After that interview, I trust them more, not less. Very humble in admitting they let the shareholders down (and not just boo we're sad).
Would be good to get some endorsement from more than one (and the same) person for a change. Otherwise, he is just like a more articulate version of moon.
I suppose we can take some solace in the fact that so far, they are doing exactly as they said they would, all seems according to plan.
Can't stand this 'host'. Constantly interrupts, mumbles.
https://www.msn.com/en-gb/money/other/why-oxford-biotech-needs-more-than-a-shot-in-the-arm-to-survive/ar-AAZo9uW
“The whole situation makes it very difficult to make your share price grow because there aren’t those long-term investors here. You get people coming in with a very short-term view. The Aim market, I’d say, is on its knees as a market for biotech.”
1-Jul-22 16:35:00 0.10 845 Buy* 0.09 0.10 0.85 O
Big spender going in for 845 shares after hours. Step aside, Elon Musk.
Does anyone know what this might be? Very strange trade.
>I'll gladly put a Rambler/chicken video out on my YouTube channel as well :)
"Don't be a c[]ck, buy Rambler stock"
Does anyone remember how in their presentation, they had '2021 will be a very different story', and then they changed the slide to be '2022 will be a very different story'. Looks like time to justify those executive salaries and correct the slide again! Haha.
https://www.theregister.com/2022/07/06/sensyne_nhs_deals/
Spotlight on NHS losses. Should bring focus and scrutiny on doing right by the shareholders.
Quote:
An Oxford University Hospital spokesperson refused to say whether it had since sold the shares. In a statement, it said: "We are in regular contact with the new management of Sensyne and they have suggested a review of the current Strategic Research Agreement (SRA) later in the year. We will carefully consider these proposals when we receive them."
Wherever they're going, I hope they get spiked and buy the tip
That is an old/existing OTC market ticker - nothing new.
The subdivision of shares document said nothing new - it's just to confirm the split into ordinary and deferred shares.
List of stakeholders possibly old.
Will be interesting to see what the subdivision of shares ends up looking like. Are they intent on going all out, as per the RNS, or will they self-restrain. And what is the ultimate ambition? $1B valuation?
And also with news of Palantir seeking to dip its toes into NHS data, what does it mean for Sensyne going forward?
https://www.ft.com/content/3f6f24f8-9e5c-42c3-8ae6-bfef5f953524
Thanks for all your posts as well - I wasn't aware I could follow the goings on via Companies House as well - interesting stuff. Any movement and development is interesting, IMO.
It doesn't look like there's anything we didn't already know, the links on the page point to Formal Sales Process Commencement Document dated Nov 2021:
https://assets.website-files.com/5cf7cc8a7a78cd65f38ad273/618eb0e2017707c5b4ad5519_Project%20Redsierra%20-%20Rule%202.11%20Letter%20-%20Shareholders.pdf